L eft ventricular hypertrophy (LVH) constitutes an independent cardiovascular risk factor, 1 which is related to a morphological and functional maladaptation. 2 The pathological changes associated with LVH, which are commonly referred to as myocardial remodeling, are characterized by myocyte growth, fibrosis, and cell death. 2 These pathological alterations have been linked, in part, to activation of the renin-angiotensin system. 2 Angiotensin II (Ang II) can induce LVH in rodents; this effect is independent of the pressor action of Ang II. 3 Angiotensin-converting enzyme (ACE) inhibitors and Ang II type 1 receptor (AT1R) antagonists prevent or regress LVH after pressure overload. 2 Therefore, it has been proposed that the hypertrophic effects of Ang II in the heart are mainly mediated through AT1R.
For growth factors, tyrosine kinase activation is an essential step in the signaling pathway for mitogenesis, such as in mitogen-activated protein (MAP) kinase. 4 However, the AT1R is not directly linked to tyrosine kinase, and yet it seems to induce tyrosine phosphorylation of multiple signaling proteins, 5, 6 suggesting a cross-talk between AT1R and a tyrosine kinase. Recently, we showed that "trans"-activation of the epidermal growth factor receptor (EGFR) through AT1R plays a key role in Ang II-induced MAP kinase/ extracellular signal-regulated kinase (ERK) activation and subsequent protein synthesis in cultured vascular smooth muscle cells (VSMCs). 7 Hence, we hypothesized that the EGFR is indispensable for Ang II-induced hypertrophic effect in vivo. An application of antisense oligodeoxynucleotide (AS-ODN) in vivo has great potential as a new tool to study the function of genes by inhibiting specific protein synthesis. 8 The present study was designed to examine the effects of an AS-ODN to EGFR (EGFR-AS) on the LVH induced by Ang II infusion and on MAP kinase/ERK activation in the heart and VSMCs.
Methods
The Institutional Animal Care and Uses Committee at the University of Florida approved all experimental procedures.
Oligodeoxynucleotides
AS-ODNs and sense oligodeoxynucleotides were designed according to principles previously described 9 as 16-mers targeted to bases Ϫ9 to ϩ7 of EGFR mRNA (GeneBank AB 025197), which were confirmed in the GeneBank database for uniqueness. The oligodeoxynucleotides were modified by phosphorothioation and synthesized by GenoMechanix.
In Vitro Experiment in VSMCs
VSMCs were prepared from the thoracic aorta of Sprague-Dawley rats (Harlan, Indianapolis, Ind) by the explant method, as previously described. 8 Cells at Ն80% confluence were made quiescent by incubation in serum-free medium for 2 days, then treated with oligodeoxynucleotides for additional 2 days. In some experiments, VSMCs grown on a 6-well plate were stimulated with Ang II at 37°C for 10 minutes. After the treatment, the medium was replaced with sodium dodecyl sulfate (SDS) sample buffer (120 L). Then, Ϸ30 L of the samples that contained same amount of proteins were loaded to SDS-PAGE. Immunoblotting was performed with enhanced chemiluminescence (Amersham) using anti-EGFR antibody, anti-ErB2 antibody, phosphospecific ERK2 antibody and ERK2 antibody (Santa Cruz Biotechnology). The ERK2 antibody is crossreactive with ERK1 to a lesser extent. All antibodies were used in 1:10 000 dilution. Quantification of the blots was determined with the use of a Quantity One Ver.4.0.1 (BioRad).
In Vivo Experiment of Ang II Infusion in Rats
Male Sprague-Dawley rats (Harlan; nϭ30) weighing 300 to 350 g were anesthetized, and an osmotic minipump (Alzet 2002) for subcutaneous infusion of Ang II (150 ng/h; Sigma) was implanted under the skin. Another osmotic minipump (Alzet 2 ML2, Alzet) was implanted for the intravenous treatment of oligodeoxynucleotides. The total dose of AS-ODN (nϭ8) or sense oligodeoxynucleotides (nϭ8) was 600 g/rat; in addition, 360 g of protamine sulfate (Sigma) and 3 mg of 1,2-bis(oleoyloxy)-3-(trimethylammonio) propane (DOTAP, Avanti Polar Lipids) with L-␣-dioleoyl phosphatidylethanolamine (DOPE, Avanti Polar Lipids) was given over 14 days. In control rats treated with Ang II without oligodeoxynucleotides, we implanted the second osmotic minipump filled with protamine sulfate/DOTAP/DOPE. Systolic blood pressure (BP) was measured by the tail-cuff method.
On day 14 after implantation of minipumps, animals were deeply anesthetized, and the left ventricles were dissected out and weighed. Aliquots of proteins (150 g) were run in SDS-polyacrylamide gel (10%) and transferred onto nitrocellulose membranes (Amersham). EGFR and phosphorylated MAP kinase (ERK) were detected by immunoblotting using 1:3000 and 1:1000 dilutions, respectively. The immunoreactive proteins were visualized using enhanced chemiluminescence (Amersham). Quantification of the blots was determined with the use of a Quantity One Ver.4.0.1 (BioRad). Data are representative of 3 separate blots, and we added histograms of relative density values from 6 readings.
Statistics
Data are expressed as meanϮSEM. Statistical analysis was performed by Student's t test or 1-way ANOVA, followed by Fisher's least significant difference method. PϽ0.05 was viewed as statistically significant.
Results
In VSMCs, the EGFR-AS specifically and dose-dependently decreased EGFR expression ( Figure 1A) , whereas it did not affect ErbB2 (a subtype of EGFR superfamily) or ERK expression. Ang II increased phosphorylated ERK, which was markedly inhibited by EGFR-AS but not by EGFR sense ( Figure 1B) .
The systolic BP was consistently increased in rats infused with Ang II compared with sham-operated rats (Figure 2A ). EGFR-AS treatment significantly decreased systolic BP compared with Ang II infusion (PϽ0.05), although systolic BP in EGFR-AS-treated rats was still higher than in sham-operated rats (Figure 2A) .
To assess LVH, the left ventricular weight to body weight ratio (LVW/BW) was determined. LVW/BW in Ang IItreated rats was larger than in sham-operated rats ( Figure 2B ). EGFR-AS treatment significantly (PϽ0.05) reduced LVW/BW compared with Ang II-infused rats, whereas EGFR-sense treatment did not alter the elevated LVW/BW ( Figure 2B ). EGFR expression and phosphorylation of ERK in the heart was increased in Ang II-infused rats compared with sham-operated rats, and EGFR-AS decreased EGFR expression and phosphorylation of ERK ( Figure 2C ). EGFRsense did not alter the elevated expression of EGFR and phosphorylated ERK.
Discussion
By using EGFR-AS as a selective inhibitor, we demonstrated for the first time that EGFR plays an essential role in Ang II-induced cardiac hypertrophy in vivo. In a previous report, EGFR seemed to be required for Ang II-mediated MAP kinase activation in vitro. 7 This was shown using a pharmacological agent, AG1478, as a specific EGFR tyrosine kinase inhibitor. 7, 10 AS-ODN is more specific than pharmacological agents because AS-ODN is a synthetic DNA with a genespecific sequence that hybridizes to the mRNA of the target gene. 8 Because cationic liposomes and cationic polymers enhance the uptake of AS-ODNs by tissue, 11, 12 DOTAP/ DOPE liposome and protamine sulfate were used in the present study. We demonstrated that these cationic polymers and lipids are also useful in increasing the antisense action either in vitro or in vivo.
Ang II stimulation of the Gq-coupled AT1R rapidly induces intracellular calcium mobilization and protein kinase C activation. 5 This mechanism was the main signaling pathway of the AT1R that elevates BP. However, Carmines et al 13 reported that AG1478 could suppress the renal arteriolar contraction responses to Ang II. To our knowledge, there has been no direct evidence that EGFR inhibition decreases BP in vivo, but a tyrosine kinase inhibitor 14 and MAP kinase kinase inhibitor 15 also attenuated the elevation of BP in Ang IIinduced hypertension. The primary ligand of EGFR, epidermal growth factor (EGF), causes the contraction of rat aorta. 16 The contractile response to EGF is augmented in hypertensive rats and is inhibited by AG1478 or MAP kinase kinase inhibitor. 17 Although EGFR-AS treatment did not normalize BP, a reduction of BP by EGFR-AS can be partially explained by an inhibition of EGFR/MAP kinase (ERK)-mediated vasoconstriction and/or a disappearance of the receptor for EGF-mediated contraction.
As we demonstrated, the inhibition of LVH by EGFR-AS may not be solely due to the inhibition of BP elevation but also due to the inhibitory effect of EGFR-AS on EGFR expression and ERK activation in the heart. Ang II infusion increases the expression of several growth factors such as heparin-binding EGF and epiregulin, which promote the growth signal by EGFR. 18 In cultured cardiac myocytes, activation of ERK is indispensable for the protein synthesis induced by Ang II. 19 In VSMCs, heparin-binding EGF generation is involved in Ang II-induced EGFR transactivation and subsequent ERK activation. 20 During the revision of this article, Asakura et al 21 showed that a metalloproteinase inhibitor attenuated the LVH caused by Ang II infusion by blocking heparin-binding EGF production. Thomas et al 22 further reported that AT1R overexpression promoted hypertrophy of cultured cardiac myocytes through an EGFR pathway. Although these publications strongly suggest the importance of EGFR in the development of LVH, our report is the first to show that Ang II activation of the EGFR-ERK pathway may be a requirement in LVH in vivo.
In summary, our results demonstrate that Ang II stimulates ERK/MAP kinase through the EGFR in vivo and in vitro. EGFR-AS inhibits this pathway and reduces both the BP and LVH induced by Ang II. EGFR-AS may therefore offer a new therapeutic intervention for the treatment of LVH and hypertension.
